Vascular Diseases  >>  pegylated liposomal doxorubicin  >>  Phase 2
Welcome,         Profile    Billing    Logout  

14 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pegylated liposomal doxorubicin / Generic mfg.
NCT00003493: Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed
2
US
dexamethasone, pegylated liposomal doxorubicin hydrochloride, vincristine sulfate
The Cleveland Clinic
Multiple Myeloma and Plasma Cell Neoplasm
 
04/04
UMCC 2004.047, NCT00116961: Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma

Completed
2
40
US
Velcade, Doxil, Dexamethasone
University of Michigan Rogel Cancer Center
Multiple Myeloma
01/07
12/07
NCT00561743: A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients

Completed
2
50
US
Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone
Janssen-Ortho Inc., Canada
Multiple Myeloma
05/07
05/07
NCT00837200: Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies

Terminated
2
13
US
Oncaspar, Doxil, Decadron, PEG-asparaginase, PEG-liposomal doxorubicin
Milton S. Hershey Medical Center
Non-hodgkins Lymphoma, Hodgkins Lymphoma, Multiple Myeloma
01/11
10/13
NCT00148317: Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma

Completed
2
38
US
Bortezomib, velcade, dexamethasone, decadron, liposomal doxorubicin, cyclophoshamide, cytoxan, filgrastim, neupogen
Weill Medical College of Cornell University, Millennium Pharmaceuticals, Inc.
Multiple Myeloma
02/11
11/12
NCT00523848: Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

Completed
2
46
US
bortezomib, pegylated liposomal doxorubicin hydrochloride, thalidomide
Roswell Park Cancer Institute
Multiple Myeloma and Plasma Cell Neoplasm
09/11
10/12
NCT00617591: Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)

Completed
2
57
US
Lenalidomide, Revlimid®, Pegylated Liposomal Doxorubicin (PLD), Doxil®, Dexamethasone, Decadron®
H. Lee Moffitt Cancer Center and Research Institute, Celgene Corporation, Ortho Biotech Clinical Affairs, L.L.C.
Multiple Myeloma
04/13
04/13
NCT01078441: Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

Terminated
2
2
US
liposomal doxorubicin, Doxil, Doxorubicin HCl Liposomal, Doxorubicin Hydrochloride Liposomal, Doxorubicin Hydrochloride Liposome, bortezomib, Velcade, PS-341, MLN-341, LDP-341, dexamethasone, Decadron, Hexadrol, Dexameth, Dexone, DXM, cyclophosphamide, CTX, Cytoxan, Neosar
National Cancer Institute (NCI)
Refractory Multiple Myeloma
02/14
03/14
NCT01492881: Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Withdrawn
2
0
US
Vorinostat, Zolina, Bortezomib, Velcade, pegylated liposomal doxorubicin, Doxil
UNC Lineberger Comprehensive Cancer Center, Merck Sharp & Dohme LLC
Multiple Myeloma
01/15
01/17
NCT00724568: Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

Completed
1/2
74
US, Canada
Lenalidomide, Revlimid, Bortezomib, Velcade, Dexamethasone, Doxil
University of Michigan Rogel Cancer Center
Multiple Myeloma
04/09
09/14
NCT00516191: A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma

Withdrawn
1/2
0
US
Liposomal Doxorubicin/Melphalan/Bortezomib, Liposomal Doxorubicin=Doxil, Melphalan=Alkeran, Bortezomib=Velcade
University of California, San Francisco
Multiple Myeloma
10/10
12/10
NCT00849251: Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Terminated
1/2
31
US
cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, pegylated liposomal doxorubicin hydrochloride, CAELYX, Dox-SL, DOXIL, doxorubicin hydrochloride liposome, LipoDox, bortezomib, LDP 341, MLN341, VELCADE, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM
University of Washington, National Cancer Institute (NCI)
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
12/11
06/15
NCT00750815: Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

Completed
1/2
58
US
Cyclophosphamide, Cytoxan, Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD), VELCADE, DOXIL®, PLD, CVDD, VDD
H. Lee Moffitt Cancer Center and Research Institute, Millennium Pharmaceuticals, Inc., Ortho Biotech, Inc.
Multiple Myeloma
12/12
05/13
NCT01246063: Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed
1/2
40
US
carfilzomib, Kyprolis, CFZ, pegylated liposomal doxorubicin (PLD), DOXIL, Dexamethasone, Decadron
Washington University School of Medicine
Multiple Myeloma
12/17
03/18

Download Options